| Signature Healthcare At Home Of S E Idaho | |
| 240 West Burnside Avenue, Suite B, Chubbuck, Idaho 83202 | |
| (208) 637-2273 | |
| Name | Signature Healthcare At Home Of S E Idaho |
|---|---|
| Location | 240 West Burnside Avenue, Suite B, Chubbuck, Idaho |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 137110 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 82930, 83201, 83202, 83203, 83204, 83205, 83210, 83211, 83217, 83221, 83228, 83232, 83234, 83236, 83237, 83239, 83241, 83243, 83245, 83246, 83250, 83252, 83254, 83256, 83261, 83262, 83263, 83271, 83274, 83276, 83277, 83285, 83286, 83287, 83401, 83402, 83404, 83406, 83434, 83440, 83442, 83445, 83448, 83451 |
| NPI Number | 1720038094 |
| Organization Name | ACCESS HOME CARE LLC |
| Address | 190 W Burnside Ave, Suite E, Chubbuck, ID 83202 |
| Phone Number | 208-637-2273 |
News Archive
DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.
Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.
The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.
› Verified 9 days ago
| NPI Number | 1790177962 |
| Organization Name | AVAMERE HOME HEALTH CARE, LLC |
| Address | 240 W Burnside Ave, Suite B, Chubbuck, ID 83202 |
| Phone Number | 208-637-2273 |
News Archive
DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.
Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.
The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.
› Verified 9 days ago
| Quality Rating: |
News Archive
DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.
Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.
The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.
› Verified 9 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 98.2 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.2 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.4 | 99.6 |
| How often the home health team checked patients for depression | 97.7 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 81.8 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 83.8 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98.7 | 96.4 |
News Archive
DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.
Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.
The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.
› Verified 9 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 89.4 | 79.6 |
| How often patients got better at getting in and out of bed | 82.5 | 81.1 |
| How often patients got better at bathing | 88.1 | 82.3 |
| How often patients’ breathing improved | 83.2 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 89 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 82.7 | 75 |
| How often home health patients had to be admitted to the hospital | 14 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 13.4 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 99.3 | 94 |
News Archive
DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.
Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.
The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.
› Verified 9 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.
Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.
The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.
› Verified 9 days ago
The patient survey data of Signature Healthcare At Home Of S E Idaho is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 88 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 79 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 87 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 85 | 78 |
News Archive
DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy.
Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.
The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.
› Verified 9 days ago
Signature Healthcare At Home Of S E Idaho Location: 240 West Burnside Avenue, Suite B, Chubbuck, Idaho 83202 Ratings: Phone: (208) 637-2273 |